X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (51) 51
humans (50) 50
male (29) 29
life sciences (27) 27
aged (23) 23
middle aged (23) 23
urology & nephrology (22) 22
cancer (21) 21
adult (20) 20
female (18) 18
immunology (17) 17
retrospective studies (14) 14
bladder cancer (12) 12
oncology (11) 11
urinary bladder neoplasms - pathology (11) 11
prognosis (10) 10
treatment outcome (10) 10
tumors (10) 10
urology (10) 10
kidney (9) 9
risk factors (9) 9
transplantation (9) 9
urinary bladder neoplasms (9) 9
aged, 80 and over (8) 8
apoptosis (8) 8
urinary bladder neoplasms - metabolism (8) 8
immunohistochemistry (7) 7
neoplasm staging (7) 7
time factors (7) 7
kidney transplantation (6) 6
progression (6) 6
surgery (6) 6
survival (6) 6
urinary bladder neoplasms - genetics (6) 6
abridged index medicus (5) 5
bladder (5) 5
care and treatment (5) 5
disease (5) 5
disease progression (5) 5
graft survival (5) 5
kaplan-meier estimate (5) 5
kidney transplantation - adverse effects (5) 5
prognostic marker (5) 5
prostatic neoplasms (5) 5
tumor markers, biological (5) 5
up-regulation (5) 5
urinary bladder neoplasms - mortality (5) 5
animals (4) 4
carcinoma (4) 4
carcinoma, transitional cell - genetics (4) 4
carcinoma, transitional cell - pathology (4) 4
cell biology (4) 4
cell line, tumor (4) 4
development and progression (4) 4
france (4) 4
gene expression regulation, neoplastic (4) 4
icsi (4) 4
metastasis (4) 4
mutation (4) 4
neoplasm invasiveness (4) 4
prostate cancer (4) 4
signal transduction (4) 4
tumor cells, cultured (4) 4
urinary bladder neoplasms - drug therapy (4) 4
urinary bladder neoplasms - surgery (4) 4
usage (4) 4
acid-binding protein (3) 3
activation (3) 3
adolescent (3) 3
aneuploidy (3) 3
apoptosis - drug effects (3) 3
biochemistry & molecular biology (3) 3
biomarkers, tumor - analysis (3) 3
biopsy (3) 3
bladder-cancer (3) 3
blotting, western (3) 3
cadherins (3) 3
cancer cells (3) 3
carcinoma in situ - mortality (3) 3
carcinoma in situ - therapy (3) 3
carcinoma, transitional cell (3) 3
carcinoma, transitional cell - metabolism (3) 3
carcinoma, transitional cell - mortality (3) 3
classification (3) 3
diagnosis (3) 3
down-regulation (3) 3
e-cadherin (3) 3
erectile dysfunction (3) 3
flow cytometry (3) 3
follow-up studies (3) 3
gene expression (3) 3
gene-expression (3) 3
genetic aspects (3) 3
health aspects (3) 3
kidney calculi - surgery (3) 3
kidney neoplasms (3) 3
kidney neoplasms - pathology (3) 3
kidney-transplantation (3) 3
kidneys (3) 3
mice (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 12, pp. e28354 - e28354
Background: Ciglitazone belongs to the thiazolidinediones class of antidiabetic drug family and is a high-affinity ligand for the Peroxisome... 
SENSITIZES TUMOR-CELLS | ACTIVATED RECEPTOR-GAMMA | HUMAN UROTHELIAL CELLS | PPAR | SURVIVIN | BIOLOGY | DOWN-REGULATION | C-FLIP | DEATH | LIGAND | PROGRESSION | Apoptosis - drug effects | Humans | Transcriptional Activation - drug effects | Urinary Bladder Neoplasms - enzymology | PPAR gamma - metabolism | G2 Phase - drug effects | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Receptors, Death Domain - metabolism | Thiazolidinediones - therapeutic use | Caspases - metabolism | Neoplasm Grading | Urinary Bladder Neoplasms - pathology | Cell Membrane - metabolism | Inhibitor of Apoptosis Proteins - metabolism | Thiazolidinediones - pharmacology | CASP8 and FADD-Like Apoptosis Regulating Protein - metabolism | BH3 Interacting Domain Death Agonist Protein - metabolism | Cell Membrane - drug effects | Hypoglycemic Agents - therapeutic use | Urinary Bladder Neoplasms - drug therapy | Enzyme Activation - drug effects | TNF-Related Apoptosis-Inducing Ligand - metabolism | Hypoglycemic Agents - pharmacology | Up-Regulation - drug effects | Xenograft Model Antitumor Assays | Animals | Mitosis - drug effects | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Line, Tumor | Mice | Proteasome Endopeptidase Complex - metabolism | Prevention | Cancer cells | Development and progression | Tumor proteins | Bladder cancer | Thiazolidinediones | Cancer | Apoptosis | Phosphorylation | p53 Protein | Bladder | Activation | Metastasis | Kinases | Cancer therapies | Cyclin B1 | Proteins | Signal transduction | Cell growth | Pathways | Urinary bladder | FLIP protein | Xenografts | Cell cycle | Down-regulation | Diabetes mellitus | Cell division | Caspase | c-FLIP protein | Pharmacology | Survivin | Tumor cell lines | Chemical compounds | Studies | Signaling | Cyclin-dependent kinase inhibitor p21 | Molecular modelling | Cell death | Medical prognosis | Cell lines | Cyclin-dependent kinase inhibitor p27 | Biomarkers | Ligands | TRAIL protein | Tumors | Index Medicus | Up-Regulation | Cell Membrane | Mitosis | Transcriptional Activation | BH3 Interacting Domain Death Agonist Protein | Urinary Bladder Neoplasms | Proteasome Endopeptidase Complex | PPAR gamma | Life Sciences | Hypoglycemic Agents | TNF-Related Apoptosis-Inducing Ligand | G2 Phase | Inhibitor of Apoptosis Proteins | Signal Transduction | Antineoplastic Combined Chemotherapy Protocols | Receptors, Death Domain | CASP8 and FADD-Like Apoptosis Regulating Protein | Caspases | Enzyme Activation
Journal Article
Tumor Biology, ISSN 1010-4283, 11/2016, Volume 37, Issue 11, p. 14789
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s13277-016-5305-6 GW501516... 
Cytochrome c | Bladder cancer | Cancer cells | Apoptosis | Cells | Cell adhesion & migration
Journal Article
Cellular Signalling, ISSN 0898-6568, 02/2014, Volume 26, Issue 2, pp. 433 - 443
Peroxisome Proliferator-Activated Receptor-β (PPARβ) is a ligand-inducible transcription factor activated by both natural (fatty acids and derivatives) and... 
Cervical cancer cells | HuR | PPARβ | p38 MAPK | VEGF | mRNA stability | P38 MAPK | MRNA stability | BLADDER-CANCER | ACTIVATED PROTEIN-KINASE | HPV-16 E6 | FACTOR EXPRESSION | PPAR beta | TUMOR ANGIOGENESIS | RICH ELEMENTS | CELL BIOLOGY | BREAST-CANCER CELLS | GENE-EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | ELAV Proteins - antagonists & inhibitors | Humans | Vascular Endothelial Growth Factor A - metabolism | RNA Stability - drug effects | RNA, Messenger - metabolism | Vascular Endothelial Growth Factor A - genetics | Tumor Suppressor Protein p53 - genetics | Vascular Endothelial Growth Factor A - chemistry | Oncogene Proteins, Viral - antagonists & inhibitors | Protein Isoforms - metabolism | PPAR-beta - agonists | RNA Interference | Human papillomavirus 18 - metabolism | Oncogene Proteins, Viral - genetics | p38 Mitogen-Activated Protein Kinases - metabolism | DNA-Binding Proteins | Oncogene Proteins, Viral - metabolism | PPAR-beta - metabolism | Signal Transduction | ELAV Proteins - metabolism | Tumor Suppressor Protein p53 - metabolism | p38 Mitogen-Activated Protein Kinases - genetics | PPAR-beta - genetics | Up-Regulation - drug effects | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Cell Line, Tumor | HeLa Cells | Phenoxyacetates - pharmacology | ELAV Proteins - genetics | Protein Isoforms - genetics | RNA, Small Interfering - metabolism | Index Medicus | Cellular | Control | Ligands | Activation | Derivatives | Gene expression | Signalling | Cancer
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 64, pp. 107744 - 107762
Known activators of the Peroxisome Proliferator-Activated Receptor gamma (PPAR gamma), thiazolidinediones (TZD) induce apoptosis in a variety of cancer cells... 
Cervical cancer cells | TRAIL | PPAR | Thiazolidinedione | Apoptosis | HPV | thiazolidinedione | cervical cancer cells | INDUCED APOPTOSIS | DOWN-REGULATION | apoptosis | TROGLITAZONE | TUMOR-CELLS | INDUCTION | PROLIFERATOR-ACTIVATED-RECEPTOR | CELL BIOLOGY | PPAR-GAMMA-LIGANDS | UP-REGULATION | THIAZOLIDINEDIONES
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 13, pp. 1192 - 1202
Dutasteride, an inhibitor of 5α-reductase in the prostate, was tested in a large, randomized trial to determine its ability to prevent prostate cancer. Over... 
MODELING APPROACH | MEDICINE, GENERAL & INTERNAL | DESIGN | THERAPY | 5-ALPHA-REDUCTASE INHIBITOR DUTASTERIDE | SENSITIVITY | FINASTERIDE | GRADE | HYPERPLASIA | PROGRESSION | PREVENTION TRIAL | Enzyme Inhibitors - adverse effects | Prostatic Neoplasms - pathology | Prostatic Hyperplasia - pathology | Double-Blind Method | Erectile Dysfunction - chemically induced | Humans | Middle Aged | 5-alpha Reductase Inhibitors | Male | Risk | Treatment Outcome | Azasteroids - therapeutic use | Enzyme Inhibitors - therapeutic use | Prostate-Specific Antigen - blood | Azasteroids - adverse effects | Prostate - pathology | Prostatic Neoplasms - genetics | Biopsy | Protein Isoforms | Dutasteride | Aged | Prostatic Neoplasms - prevention & control | Prostatic Hyperplasia - drug therapy | Heart Failure - chemically induced | Usage | Diagnosis | Health aspects | Prostate cancer | Risk factors | Patient safety | Age | Men | Tumors | Index Medicus | Abridged Index Medicus | Prostate-Specific Antigen | Erectile Dysfunction | Enzyme Inhibitors | Testosterone 5-alpha-Reductase | Prostatic Hyperplasia | Life Sciences | Prostatic Neoplasms | Azasteroids | Heart Failure | Prostate | Cancer | pathology | genetics | Urologi och njurmedicin | chemically induced | drug therapy | prevention & control | blood | adverse effects | Cancer and Oncology | Urology and Nephrology | therapeutic use | Cancer och onkologi
Journal Article
Journal Article
Journal Article